Paroxetine Rapidly Modulates the Expression of Brain-Derived Neurotrophic Factor mRNA and Protein in a Human Glioblastoma-Astrocytoma Cell Line
The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Neuronal upregulation of the brain-derived neurotrophic factor (BDNF) gene appears to be a crucial factor for the efficacy of antidepressants. However, besides neurons, little information is present on the modulation of BDNF by antidepressants at RNA and protein levels in other cell types of the central nervous system. Glial cells are able to store and release BDNF, and it has been hypothesized that glial dysfunction may contribute to the etiopathogenesis of depression. Thus, in this study we used the human glioblastoma-astrocytoma cell line U87 exposed to the antidepressant drug paroxetine, and evaluated BDNF mRNA and protein expression. In addition, since the BDNF gene can be posttranscriptionally modulated by a family of microRNA, we also evaluated the levels for one of these microRNA (miR-30a-5p) in the U87 cell line during paroxetine treatment. We found that paroxetine treatment rapidly increased BDNF in U87 cells, resulting from an induction of BDNF mRNA expression and de novo protein synthesis, and that these increases occurred in a time-dependent manner. Paroxetine effects were evident at 6 h of incubation for BDNF mRNA and at 12 h for BDNF protein. In addition, the transcriptional BDNF inhibitor miR-30a-5p was also overexpressed at 6 and 12 h of paroxetine incubation. These findings indicate that the U87 cell line, an in vitro model of glial cells, rapidly responds to paroxetine by increasing BDNF production, and that these effects are potentially limited by microRNA induction. These data may contribute to explain the action of paroxetine on cells of nonneuronal origin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action
Tsankova, N. M., Berton, O., Renthal, W., Kumar, A., Neve, R. L., & Nestler, E. J. (2006) · Nature Neuroscience · doi:10.1038/nn1659 · Cited by 1,780
New approaches to antidepressant drug discovery: beyond monoamines
Berton, O., & Nestler, E. J. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1846 · Cited by 1,589 · cited 1×
“The therapeutic action of SSRI has been attributed to neuroadaptive mechanisms, which involve changes in signal transduction, modulation of gene expression and stimulation of neurogenesis [”
BackgroundGlial reduction in the subgenual prefrontal cortex in mood disorders
Öngür, D., Drevets, W. C., & Price, J. L. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.22.13290 · Cited by 1,525 · cited 1×
“More intriguing, it has been hypothesized that glial dysfunction may contribute to the etiopathogenesis of depression [”
BackgroundRajkowska, G., Miguel-Hidalgo, J. J., Wei, J., Dilley, G., Pittman, S. D., Meltzer, H. Y., Overholser, J. C., Roth, B. L., & Stockmeier, C. A. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00041-4 · Cited by 1,477
Sen, S., Duman, R., & Sanacora, G. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.05.005 · Cited by 1,232
Saarelainen, T., Hendolin, P., Lucas, G., Koponen, E., Sairanen, M., MacDonald, E., Agerman, K., Haapasalo, A., Nawa, H., Aloyz, R., et al. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-01-00349.2003 · Cited by 800
Essential role of brain-derived neurotrophic factor in adult hippocampal function
Monteggia, L. M., Barrot, M., Powell, C. M., Berton, O., Galanis, V., Gemelli, T., Meuth, S., Nagy, A., Greene, R. W., & Nestler, E. J. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402141101 · Cited by 685 · cited 1×
“Consistently, transgenic mice with impaired BDNF synthesis fail to respond to antidepressant drugs [”
BackgroundCastrén, E. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1629 · Cited by 563
Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs)
Hyttel, J. (1994) · International Clinical Psychopharmacology · doi:10.1097/00004850-199403001-00004 · Cited by 492 · cited 1×
“which selectively and powerfully inhibit serotonin reuptake, thus resulting in a potentiation of serotonergic neurotransmission [”
BackgroundTardito, D., Perez, J., Tiraboschi, E., Musazzi, L., Racagni, G., & Popoli, M. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.1.7 · Cited by 303
Mellios, N., Huang, H.-S., Grigorenko, A., Rogaev, E., & Akbarian, S. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddn201 · Cited by 274 · cited 1×
“Thus, in order to investigate the effects of SSRI on BDNF of glial origin, in this study we used the human glioblastoma-astrocytoma cell line U87 cultured in the presence of paroxetine during a 48-hour time course, and evaluated BDNF mRNA and protein levels. In addition, since it has recently been shown that the BDNF…”
MethodMüller, M. B., Lucassen, P. J., Yassouridis, A., Hoogendijk, W. J. G., Holsboer, F., & Swaab, D. F. (2001) · European Journal of Neuroscience · doi:10.1046/j.0953-816x.2001.01784.x · Cited by 249
Djalali, S., Höltje, M., Große, G., Rothe, T., Stroh, T., Große, J., Deng, D. R., Hellweg, R., Grantyn, R., Hörtnagl, H., et al. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02911.x · Cited by 130 · cited 1×
“BDNF is a potent trophic agent for serotonergic neurons [”
BackgroundKoponen, E., Rantamäki, T., Voikar, V., Saarelainen, T., MacDonald, E., & Castrén, E. (2005) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-005-8468-z · Cited by 125
Bramham, C. R. (2007) · Progress in Brain Research · doi:10.1016/s0079-6123(07)63025-8 · Cited by 69
Paroxetine: current status in psychiatry
Pae, C.-U., & Patkar, A. A. (2007) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.7.2.107 · Cited by 53 · cited 1×
“It has approved indications for the treatment of major depression, obsessive-compulsive disorder, panic disorder, generalized anxiety disorder, posttraumatic stress disorder and social phobia in adults. Long-term data suggest that paroxetine is effective in preventing relapse or recurrence of depression for up to 1 ye…”
Background
Cited by
Baldessarini, R. J. (2013) · doi:10.1007/978-1-4614-3710-9 · Cited by 365
Quesseveur, G., David, D. J., Gaillard, M. C., Pla, P., Wu, M. V., Nguyen, H. T., Nicolas, V, Auregan, G., David, I., Dranovsky, A., et al. (2013) · Translational Psychiatry · doi:10.1038/tp.2013.30 · Cited by 235
Wan, Y., Liu, Y., Wang, X., Wu, J., Liu, K., Zhou, J., Liu, L., & Zhang, C. (2015) · PLOS ONE · doi:10.1371/journal.pone.0121975 · Cited by 182
Duclot, F., & Kabbaj, M. (2015) · Journal of Experimental Biology · doi:10.1242/jeb.107086 · Cited by 103
The importance of epigenetics in diagnostics and treatment of major depressive disorder
Czarny, P., Białek, K., Ziółkowska, S., Strycharz, J., Barszczewska, G., & Sliwinski, T. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11030167 · Cited by 37
Metadata
- Authors
- Angelucci, F., Croce, N., Spalletta, G., Dinallo, V., Gravina, P., Bossù, P., Federici, G., Caltagirone, C., & Bernardini, S.
- Venue
- Pharmacology
- Publisher
- S. Karger AG
- Published
- 2010-12-20
- Volume
- 87
- Issue
- 1-2
- Pages
- 5-10
- ISSN
- 0031-7012 (ISSN-L)
- 1423-0313
- OpenAlex
- W1970394448
- Cited by
- 33
- References
- 16
- FWCI
- 2.05
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.